002038 双鹭药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-5.047-6.457-1.3027.3964.349
总资产报酬率 ROA (%)-4.496-5.762-1.2096.8574.029
投入资产回报率 ROIC (%)-4.707-6.027-1.2767.2774.290

边际利润分析
销售毛利率 (%)60.75662.14467.97081.56085.054
营业利润率 (%)-120.450-44.783-18.11046.92625.074
息税前利润/营业总收入 (%)-118.442-45.375-21.37944.19423.276
净利润/营业总收入 (%)-101.721-55.835-11.40040.74821.743

收益指标分析
经营活动净收益/利润总额(%)-0.9271.883-29.16454.32773.458
价值变动净收益/利润总额(%)102.521-132.013119.00351.51038.535
营业外收支净额/利润总额(%)-1.825-0.41010.577-2.791-1.529

偿债能力分析
流动比率 (X)7.7812.8708.6007.0726.916
速动比率 (X)7.0801.9367.7496.6856.443
资产负债率 (%)6.47814.5506.6637.4506.750
带息债务/全部投入资本 (%)-0.7958.2050.4860.091-0.435
股东权益/带息债务 (%)-12,329.2581,086.48020,066.410108,232.141-22,658.472
股东权益/负债合计 (%)1,441.744586.4671,398.8081,240.1781,378.734
利息保障倍数 (X)780.49458.56418.970-30.320-16.394

营运能力分析
应收账款周转天数 (天)56.03352.96782.70380.077102.567
存货周转天数 (天)750.869707.645332.536269.611300.065